Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Adenosine
Drug ID BADD_D00045
Description The structure of adenosine was first described in 1931,[A229823] though the vasodilating effects were not described in literature until the 1940s.[A229828] Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy,[L31983] though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia.[L31998] Adenosine was granted FDA approval on 30 October 1989.[L31978]
Indications and Usage Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT.
Marketing Status Prescription; Discontinued
ATC Code C01EB10
DrugBank ID DB00640
KEGG ID D00045
MeSH ID D000241
PubChem ID 60961
TTD Drug ID D06IAR
NDC Product Code 16714-180; 67457-859; 82083-0011; 25021-301; 72211-004; 72397-010; 73590-0076; 73113-030; 82083-0008; 73590-0080; 72371-030; 68083-157; 81710-040; 73590-0040; 63323-651; 73590-0039; 73590-0035; 70930-504; 51662-1450; 17478-953; 72371-010; 67457-857; 55150-192; 62041-300; 73509-020; 73590-0038; 70930-502; 73590-0054; 23155-258; 73590-0079; 69153-070; 82083-0009; 55150-193; 73590-0037; 67457-855; 0703-8776; 51346-537; 52584-026; 12562-3021; 0409-1932; 71872-7035; 17478-544; 71080-0024; 73590-0078; 71872-7099; 81710-080; 73590-0081; 0703-8777; 71080-0027; 60611-0120; 76731-212; 68083-101; 72371-020; 74647-0005; 71711-0005; 67457-856; 51662-1345; 81710-050; 0641-6113; 81689-040; 73590-0033; 82083-0007; 68083-156; 70518-2778; 73590-0048; 73590-0036; 0404-9809; 42491-1200; 81758-010; 73590-0032; 67457-858; 73590-0051; 73590-0034; 73509-010; 62041-290; 71872-7209; 81647-150; 51662-1511; 0469-8234; 17478-542; 67457-854; 81647-130; 42491-1100; 71006-090; 73590-0077; 58623-0061; 73590-0031; 81710-020; 82428-010; 16714-972; 14593-933
Synonyms Adenosine | Adenocard | Adenoscan
Chemical Information
Molecular Formula C10H13N5O4
CAS Registry Number 5536-17-4
SMILES C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisTyrosine-protein phosphatase non-receptor type 12Q05209Not Available11000134; 12686737; 11226388; 11159014
Cell deathL-lactate dehydrogenase A chainP00338T150533261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
Cytogenetic abnormalityL-lactate dehydrogenase A chainP00338T150533261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
Disorders of purine metabolismDeoxyribonuclease-1P49183Not Available3261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
Disorders of purine metabolismPurine nucleoside phosphorylaseP00491T781983261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
Disorders of purine metabolismAdenosine deaminaseP00813T036613261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
Disorders of purine metabolismAdenosine deaminaseP00813T0366110069416; 10845921; 11435465
ImmunodeficiencyAdenosine deaminaseP00813T0366110069416; 10845921; 11435465
ImmunodeficiencyAdenosine deaminaseP00813T036613261757; 1282508; 7686540; 2506269; 6332827; 6808516; 8288444; 6810516; 6317746; 6424727; 9213430; 7969076
PainMitogen-activated protein kinase 11Q15759T5572914978347; 15469044; 12917686
PainP2X purinoceptor 4P51577Not Available14978347; 15469044; 12917686
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.000371%Not Available
Agitation19.06.02.001; 17.02.05.012--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Apnoea22.02.01.001--
Arrhythmia02.03.02.001--Not Available
Arteriospasm coronary24.04.04.005; 02.02.02.0050.002225%Not Available
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.0020.001113%
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block complete02.03.01.0030.000371%
Atrioventricular block first degree02.03.01.004--
Atrioventricular block second degree02.03.01.005--
Back pain15.03.04.005--
Blood pressure increased13.14.03.005--Not Available
Bradycardia02.03.02.0020.001484%Not Available
Bronchospasm22.03.01.004; 10.01.03.0120.001855%
Bundle branch block right02.03.01.0110.000371%Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiac arrest02.03.04.0010.000290%
Cardiac failure02.05.01.0010.000194%
Cardiac output decreased13.14.02.0010.000742%Not Available
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.000097%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort08.01.08.019; 02.02.02.009; 22.02.08.001--Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.0030.000371%Not Available
Chronic obstructive pulmonary disease22.03.01.0070.000097%Not Available
Circulatory collapse24.06.02.0010.000927%Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages